Persistence on monthly zoledronic acid impacts risk and frequency of skeletal complications and follow-up duration in lung cancer patients

被引：0
|
作者：
Hatoum, Hind T. [1 ,2 ]
Lin, Swu-Jane [1 ,2 ]
Lipton, Allan [3 ]
Guo, Amy [4 ]
Smith, Matthew R. [5 ]
机构：
[1] Hind T Hatoum & Co, Chicago, IL USA
[2] Univ Illinois, Chicago, IL USA
[3] Hershey Med Ctr, Hershey, PA USA
[4] Novartis Pharmaceut, Florham Pk, NJ USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S432 / S433
页数：2
相关论文
共 50 条
  • [21] Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases
    不详
    BREAST, 2005, 14 : S44 - S44
  • [22] Evidence-based follow-up of lung cancer patients
    Smith, TJ
    SEMINARS IN ONCOLOGY, 2003, 30 (03) : 361 - 368
  • [23] Risk factors and temporal patterns of recurrences in patients with vulvar cancer: implications for follow-up intervals and duration
    Rohrmoser, Katharina
    Ignatov, Atanas
    Gerken, Michael
    Ortmann, Olaf
    Klinkhammer-Schalke, Monika
    Papathemelis, Thomas
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 803 - 810
  • [24] Cancer Risk in Nodules Detected at Follow-Up Lung Cancer Screening CT
    Hammer, Mark M.
    Byrne, Suzanne C.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2022, 218 (04) : 634 - 641
  • [25] Risk factors and temporal patterns of recurrences in patients with vulvar cancer: implications for follow-up intervals and duration
    Katharina Röhrmoser
    Atanas Ignatov
    Michael Gerken
    Olaf Ortmann
    Monika Klinkhammer-Schalke
    Thomas Papathemelis
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 803 - 810
  • [26] Zoledronic acid reduces long-term risk of skeletal complications in patients with advanced renal cell carcinoma or bladder cancer
    Mulders, Peter F.
    Miller, Kurt
    Tchekmedyian, N. Simon
    JOURNAL OF UROLOGY, 2007, 177 (04): : 429 - 430
  • [27] Pleural plaques and risk of lung cancer: A prospective follow-up study
    Hillerdal, GN
    CHEST, 2005, 128 (04) : 333S - 333S
  • [28] Follow-up examination in chronic inflammatory disease: complications, sequelae and cancer risk
    Hartmann, F
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2001, 126 : S59 - S63
  • [29] Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone
    Saad, F
    Gleason, D
    Murray, R
    Venner, P
    Tchekmedyian, S
    Lacombe, L
    Chin, J
    Vinholes, J
    Goas, JA
    Chen, BL
    Seaman, J
    JOURNAL OF UROLOGY, 2003, 169 (04): : 394 - 394
  • [30] Clinical benefit of zoledronic acid (Zol) in patients (pts) with lung cancer and other solid tumors based on prior history of skeletal complications
    Hirsh, Vera
    Tchekmedyian, N. Simon
    Rosen, Lee S.
    Zheng, Ming
    Hei, Yong-Jiang
    ANNALS OF ONCOLOGY, 2004, 15 : 189 - 189
12345